Hearing Loss: Targeted Mitochondrial Mutation Panel

**Test Code:** QJ  
**Turnaround time:** 3 weeks  
**CPT Codes:** 81254 x1

### Condition Description

- Approximately 1 in 1000 children are diagnosed with prelingual hearing loss (HL) or deafness. Approximately half of prelingual hearing loss or deafness is attributed to environmental exposures and the remaining half to genetic causes. Approximately 30% of hereditary hearing loss is estimated to be syndromic (associated with other birth defects) while the remaining 70% is non-syndromic (isolated and not associated with other findings). Non-syndromic deafness is mainly due to recessive genes (75-80%), and over 20 such genes have been identified. Non-syndromic hearing loss may also be inherited in autosomal dominant, X-linked, or mitochondrial patterns.

- In the presence of specific mitochondrial DNA mutations, moderate to severe hearing loss can result from exposure to aminoglycoside antibiotics such as gentamicin, tobramycin, amikacin, kanamycin, or streptomycin [1]. Bilateral severe hearing loss can occur within a few days to weeks of exposure to an amniglycoside. Aminoglycoside ototoxicity mitochondrial mutations cause sensorineural hearing loss during childhood or early adulthood even in the absence of amniglycoside exposure. Patients may or may not have a family history of hearing loss and typically do not have any other physical findings [2]. Mutations in the mitochondrial *MTRNR1* and *MTTS1* genes have been associated with aminoglycoside ototoxicity in an estimated 2% of deaf individuals in the US [3, 4]. The prevalence is higher, 15-30%, among deaf persons with a history of aminoglycoside exposure [5].

- One of the most common mitochondrial mutations is the A1555G substitution in the 12S ribosomal RNA subunit gene (*MTRNR1* gene) which can be found in 0.6-2.5% of Caucasian, 3-5% of Asian and as high as 17% of Spanish population with non-syndromic hearing loss [6]. Approximately 21% of individuals with mitochondrial nonsyndromic hearing loss have the 1555A>G mutation in *MTRNR1* and 50% have the 961delT(C)n. The 1555A>G mutation occurs in a homoplastic state and the penetrance of hearing loss following amniglycoside exposure is 100%. Without amniglycoside exposure the penetrance of 1555A>G at age 65 is 80%.

- The 7,445A>G/7,443A>G/7,444G>A mutations in the tRNA serine gene (*MTTS1*) have been found in patients with maternally inherited sensorineural hearing loss, but they are less likely to cause aminoglycoside hypersensitivity. Of individuals with mitochondrial nonsyndromic hearing loss, 14% have *MTTS1* mutations 7443A>G, 7444A>G, or 7445A>G.

- Most mitochondrial DNA mutations causing non-syndromic hearing loss are maternally inherited. Hetoplastic states (uneven distribution of mitochondrial DNA during cell division) and variable penetrance may be related to the level of mutant mitochondria present, and is not quantitated by this assay. *MTTS1* mutations may occur in heteroplastic states and penetrance may be related to the level of mutant mitochondria (not quantitated by this assay).

### This test analyzes four different mutations in the *MTRNR1* and *MTTS1* genes that have been shown to be involved in non-syndromic hearing loss.

Please [click here](#) for the GeneReviews summary on this condition.

### References:

### Genes

*MTRNR1, MTTS1*

### Indications

This test is indicated for:

- **Individuals with clinical symptoms of non-syndromic hearing loss especially if triggered by aminoglycoside antibiotics.**
- **Carrier testing in individuals with a maternal family history of aminoglycoside related hearing loss.**

### Methodology

1555 (12S rRNA) and 7443/7444/7445 (tRNA Serine) mutations are assayed by PCR and restriction fragment analysis.

### Detection

The A1555G substitution in the *MTRNR1* gene can be found in 0.62.5% of Caucasian, 3-5% of Asian and as high as 17% of Spanish population with non-syndromic HL [7]. This assay is estimated to detect about 35% cases of all mitochondrial non-syndromic hearing loss.

### Reference Range

Qualitative assay.
Specimen Requirements

Submit only 1 of the following specimen types

* Preferred specimen type: Whole Blood

**Type: Whole Blood**

Specimen Requirements:

In EDTA (purple top) tube:
Infants (2 years): 3-5 ml
Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Type: Saliva**

Specimen Requirements:

Oragene™ Saliva Collection kit (available through EGL) used according to manufacturer instructions.

Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

**Related Tests**

- **Hearing Loss: Comprehensive Panel (HL)** is indicated for patients who have not have previous molecular testing and includes sequencing of the GJB2 and GJB6 genes, targeted mutation analysis of the GJB6 common 342kb deletion, and testing for mitochondrial mutations associated with aminoglycoside sensitivity.
- **Known Mutation Testing (KM)** is available to family members if mutations are identified by sequencing.
- Prenatal testing is available to couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.